The global market for heart valve replacement procedures is around 225,000 annually

(http://www.medsolution.com/surgery_cardiothoracic-heartvalv.asp)

An average of 425 people each day or one every three minutes will die from Cardiovascular (heart and circulatory) disease (CVD)  in the UK. In adult patients the aortic valve tends to be the main area of concern, with the pulmonary valves being problematic in younger patients. However, it has been said ‘In younger patients, nearly 65% of Homografts [human organ substitutes] degenerate after 5 years’.

This highlights the need for a longer lasting biologic heart valve replacement which could prevent the trauma of a reoperation.

The dCELL® heart valve regenerates to become part of the patient’s body, providing a more durable repair with a significantly reduced risk of rejection and infection.

It is not just the physical and emotional implications to the patients, but the increasing economic burden on healthcare systems around the world. The British Heart Foundation estimates that the healthcare costs in the UK alone associated with CVD to be up at £11bn.

As average life expectancy increases, so too does the expectation to remain physically active with a high quality of life for much longer.  The freedom from reoperation or anti-rejection and anti-coagulation drugs allows patients to lead almost a completely normal life being physically active. It could also significantly reduce the economic consequences of this problem.

The results of Professor Francisco da Costa’s pioneering work at the Pontifical Catholic University of Paraná (PUCPR), and the Santa Casa hospital, Brazil, relating to CardioPure dCELL® pulmonary and aortic heart valves confirms the success of dCELL® in this field based on over 10 years of clinical data.

Key findings

The ten year follow up clinical data from Brazil presented by Professor Francisco da Costa revealed excellent and exciting results. These were particularly significant given the average age of these patients was young, and the majority were considered to be high risk. 

The data showed:

  1. Freedom from reoperation in the high risk aortic group was 89% after ten years.
  2. Partial cellular repopulation of the valve.
  3. Younger age and lower body weight were not associated with increased late gradients
  4. No immunogenic reaction and consequently CT scans showed absence of calcification even in the valve root, essential in this treatment, where, in younger patients, it is a significant problem.

You may also be interested in